4D Molecular Therapeutics, Inc.
FDMT4D Molecular Therapeutics, Inc. in brief
4D Molecular Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Emeryville, California, USA. Its market value was $637 M on 1 August 2026, which makes it the 11,522nd largest listed company in the world and the 2,378th largest in the USA on this site. In the year to December 2025 it had sales of $85 M and a net loss of $140 M. It employs about 78 people and David Kirn is its chief executive. Its largest product and service lines by sales in 2025 were Collaboration and License Revenue (100%). By market, the largest shares of its 2025 sales came from Japan (100%) and USA (under 1%). Its shares trade under the symbol FDMT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics is an Innovative Gene Therapy company designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions. The company annual revenue is 6.99 million USD and 78 employees as on 2019. The headquarters is in USA.
4D Molecular Therapeutics, Inc. timeline
- 2015
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 🔔Initial public offering on Nasdaq as FDMTFinal prospectus filed with the SEC on 14 December 2020; shares registered for exchange trading on 8 December 2020.
- 2025
- 💰Record revenue of $85 millionFY2025, the highest of the 6 years on record.
Events of 4D Molecular Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,077 (Jan 2021) · #3,049 (Jan 2022) · #2,305 (Dec 2022) · #2,326 (Jul 2023) · #2,135 (Jan 2024) · #1,244 (Mar 2026) · #2,379 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 6.6×
- Price / book
- 1.3×
- Free cash flow yield
- -17.2%
- Net margin (TTM)
- -208.6%
- Operating margin
- -187.2%
- Return on equity
- -39.6%
- Liabilities / assets
- 10.8%
- Net debt
- $-60M
- Revenue growth
- +212925.0%
- R&D / revenue
- 229.7%
- Revenue per employee
- $1.1 M
- Profit per employee
- $-1.8 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $85M | +212925.0% | $-160M | $-140M | -164.4% |
| Dec 2024 | $0M | -99.8% | $-188M | $-161M | -402175.0% |
| Dec 2023 | $21M | — | $-113M | $-101M | -486.7% |
| Dec 2022 | — | — | $-110M | $-107M | — |
| Dec 2021 | $18M | +32.5% | $-71M | $-71M | -395.3% |
| Dec 2020 | $14M | +94.7% | $-57M | $-57M | -416.5% |
| Dec 2019 | $7M | — | $-51M | $-49M | -705.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-109M | $1M | $-110M | $-2.42 | — |
| Dec 2024 | $-135M | $4M | $-138M | $-2.98 | — |
| Dec 2023 | $-76M | $3M | $-79M | $-2.58 | — |
| Dec 2022 | $-87M | $12M | $-98M | $-3.32 | — |
| Dec 2021 | $-69M | $9M | $-78M | $-2.57 | — |
| Dec 2020 | $-51M | $1M | $-52M | $-8.82 | — |
| Dec 2019 | $-37M | $3M | $-40M | $-9.59 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $4M (+4500.0% on a year earlier), net income $-78M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 28, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jul 20, 20268-KCurrent reportOther events
- Jun 29, 20268-KCurrent reportMaterial agreement · New financial obligation
- Jun 22, 20268-KCurrent reportShareholder vote
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent reportDirectors or officers changed
Official filings of 4D Molecular Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $85 M
- Operating income
- $-160 M
- Net income
- $-140 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $567 M
- Total liabilities
- $61 M
- Total equity
- $506 M
As of December-2025
Top 100 institutional investors in 4D Molecular Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd. | 5,734,905 | — | 9.08% | $82 M | Nov 16, 2026 |
| 2 | Ra Capital Management, L.P. | 5,049,779 | 0 (0.00%) | 8.00% | $72 M | Nov 16, 2026 |
| 3 | BlackRock, Inc. | 4,724,904 | +178,845 (+3.93%) | 7.48% | $68 M | Nov 13, 2026 |
| 4 | Goldman Sachs Group Inc | 3,930,407 | -328,261 (-7.71%) | 6.23% | $56 M | Nov 16, 2026 |
| 5 | Novo Holdings A/s | 3,000,000 | -249,178 (-7.67%) | 4.75% | $43 M | Nov 16, 2026 |
| 6 | BVF Inc/il | 2,879,289 | 0 (0.00%) | 4.56% | $41 M | Nov 16, 2026 |
| 7 | State Street Corp | 2,469,425 | -441,684 (-15.17%) | 3.91% | $35 M | Nov 12, 2026 |
| 8 | Adage Capital Partners GP, L.L.C. | 2,289,203 | +40,000 (+1.78%) | 3.63% | $33 M | Nov 16, 2026 |
| 9 | T. Rowe Price Investment Management, Inc. | 2,266,034 | -245,853 (-9.79%) | 3.59% | $32 M | Nov 16, 2026 |
| 10 | Trails Edge Capital Partners, LP | 2,227,917 | 0 (0.00%) | 3.53% | $32 M | Nov 16, 2026 |
| 11 | Vanguard Capital Management LLC | 2,140,758 | +41,703 (+1.99%) | 3.39% | $31 M | Nov 13, 2026 |
| 12 | Armistice Capital, LLC | 1,950,000 | -50,000 (-2.50%) | 3.09% | $28 M | Nov 16, 2026 |
| 13 | Bank Of America Corp /de/ | 1,534,999 | +414,325 (+36.97%) | 2.43% | $22 M | Nov 16, 2026 |
| 14 | Geode Capital Management, LLC | 1,184,271 | +55,805 (+4.95%) | 1.88% | $17 M | Nov 6, 2026 |
| 15 | Morgan Stanley | 1,090,649 | +587,629 (+116.82%) | 1.73% | $16 M | Nov 13, 2026 |
| 16 | Evergreen Quality Fund GP, Ltd. | 951,474 | 0 (0.00%) | 1.51% | $14 M | Nov 16, 2026 |
| 17 | Dimensional Fund Advisors LP | 787,000 | +56,143 (+7.68%) | 1.25% | $11 M | Nov 4, 2026 |
| 18 | Parkman Healthcare Partners LLC | 772,177 | -176,007 (-18.56%) | 1.22% | $11 M | Nov 16, 2026 |
| 19 | Catalio Capital Management, LP | 684,753 | +213,499 (+45.30%) | 1.08% | $10 M | Nov 16, 2026 |
| 20 | Vanguard Portfolio Management LLC | 578,930 | -973 (-0.17%) | 0.92% | $8 M | Nov 13, 2026 |
| 21 | Deutsche Bank AG\ | 546,088 | -164,854 (-23.19%) | 0.86% | $8 M | Nov 6, 2026 |
| 22 | Northern Trust Corp | 540,163 | -22,766 (-4.04%) | 0.86% | $8 M | Nov 16, 2026 |
| 23 | Acuta Capital Partners, LLC | 535,109 | +27,308 (+5.38%) | 0.85% | $8 M | Nov 16, 2026 |
| 24 | Charles Schwab Investment Management Inc | 438,712 | +99,437 (+29.31%) | 0.69% | $6 M | Nov 16, 2026 |
| 25 | Diadema Partners LP | 421,107 | -150,000 (-26.26%) | 0.67% | $6 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Renaissance Technologies LLC | 411,786 | -202,787 (-33.00%) | 0.65% | $6 M | Nov 12, 2026 |
| 27 | Jpmorgan Chase & Co | 393,029 | -9,108 (-2.26%) | 0.62% | $6 M | Nov 12, 2026 |
| 28 | Nuveen, LLC | 390,869 | -112,202 (-22.30%) | 0.62% | $6 M | Nov 10, 2026 |
| 29 | Opaleye Management Inc. | 334,437 | 0 (0.00%) | 0.53% | $5 M | Nov 16, 2026 |
| 30 | FMR LLC | 311,944 | +183,628 (+143.11%) | 0.49% | $4 M | Nov 10, 2026 |
| 31 | HRT Financial LP | 305,926 | New | 0.48% | $4 M | Nov 13, 2026 |
| 32 | Vanguard Fiduciary Trust Co | 300,719 | +24,481 (+8.86%) | 0.48% | $4 M | Nov 13, 2026 |
| 33 | Burkehill Global Management, LP | 275,000 | 0 (0.00%) | 0.44% | $4 M | Nov 16, 2026 |
| 34 | Invesco Ltd. | 260,116 | +109,734 (+72.97%) | 0.41% | $4 M | Nov 12, 2026 |
| 35 | Raymond James Financial Inc | 241,860 | -489 (-0.20%) | 0.38% | $3 M | Nov 12, 2026 |
| 36 | Brevan Howard Capital Management LP | 203,800 | +26,950 (+15.24%) | 0.32% | $3 M | Nov 16, 2026 |
| 37 | ArrowMark Colorado Holdings LLC | 202,864 | 0 (0.00%) | 0.32% | $3 M | Nov 16, 2026 |
| 38 | Woodline Partners LP | 200,001 | 0 (0.00%) | 0.32% | $3 M | Nov 16, 2026 |
| 39 | Voya Investment Management LLC | 191,868 | +51,668 (+36.85%) | 0.30% | $3 M | Nov 10, 2026 |
| 40 | Barclays PLC | 179,867 | +156,042 (+654.95%) | 0.28% | $3 M | Nov 6, 2026 |
| 41 | Propel Bio Management, LLC | 179,154 | -73,500 (-29.09%) | 0.28% | $3 M | Nov 13, 2026 |
| 42 | Federated Hermes, Inc. | 176,677 | -45,739 (-20.56%) | 0.28% | $3 M | Nov 12, 2026 |
| 43 | Schonfeld Strategic Advisors LLC | 175,180 | -232,290 (-57.01%) | 0.28% | $3 M | Nov 16, 2026 |
| 44 | Jane Street Group, LLC | 171,009 | New | 0.27% | $2 M | Nov 12, 2026 |
| 45 | Wellington Management Group LLP | 162,802 | +34,338 (+26.73%) | 0.26% | $2 M | Nov 16, 2026 |
| 46 | Citadel Advisors LLC | 154,311 | -533,286 (-77.56%) | 0.24% | $2 M | Nov 16, 2026 |
| 47 | Bank of New York Mellon Corp | 152,578 | +241 (+0.16%) | 0.24% | $2 M | Nov 5, 2026 |
| 48 | Greenland Capital Management LP | 151,762 | +79,505 (+110.03%) | 0.24% | $2 M | Nov 16, 2026 |
| 49 | Ikarian Capital, LLC | 150,037 | New | 0.24% | $2 M | Nov 16, 2026 |
| 50 | Trexquant Investment LP | 148,305 | New | 0.23% | $2 M | Nov 16, 2026 |
| 51 | Perigon Wealth Management, LLC | 146,185 | 0 (0.00%) | 0.23% | $2 M | Oct 22, 2026 |
| 52 | Millennium Management LLC | 136,373 | New | 0.22% | $2 M | Nov 16, 2026 |
| 53 | American Century Companies Inc | 127,965 | +13,965 (+12.25%) | 0.20% | $2 M | Nov 12, 2026 |
| 54 | Susquehanna International Group, LLP | 122,351 | +110,190 (+906.09%) | 0.19% | $2 M | Nov 16, 2026 |
| 55 | UBS Group AG | 118,127 | -138,546 (-53.98%) | 0.19% | $2 M | Nov 10, 2026 |
| 56 | Susquehanna Portfolio Strategies, LLC | 110,985 | +4,050 (+3.79%) | 0.18% | $2 M | Nov 16, 2026 |
| 57 | Persistent Asset Partners Ltd | 106,954 | -38,631 (-26.54%) | 0.17% | $2 M | Nov 13, 2026 |
| 58 | Hussman Strategic Advisors, Inc. | 105,000 | New | 0.17% | $2 M | Nov 2, 2026 |
| 59 | Two Sigma Investments, LP | 93,432 | +23,951 (+34.47%) | 0.15% | $1 M | Nov 16, 2026 |
| 60 | Privium Fund Management B.V. | 90,110 | 0 (0.00%) | 0.14% | $1 M | Nov 3, 2026 |
| 61 | State Of Wisconsin Investment Board | 83,762 | +27,510 (+48.90%) | 0.13% | $1 M | Nov 16, 2026 |
| 62 | Assenagon Asset Management S.A. | 83,333 | -83,333 (-50.00%) | 0.13% | $1 M | Oct 15, 2026 |
| 63 | Acadian Asset Management LLC | 82,927 | -80,618 (-49.29%) | 0.13% | $1 M | Nov 9, 2026 |
| 64 | Citigroup Inc | 75,204 | +5,992 (+8.66%) | 0.12% | $1 M | Nov 4, 2026 |
| 65 | Alps Advisors Inc | 73,175 | +20,119 (+37.92%) | 0.12% | $1 M | Nov 3, 2026 |
| 66 | DekaBank Deutsche Girozentrale | 61,000 | +31,000 (+103.33%) | 0.10% | $1 M | Oct 27, 2026 |
| 67 | TD Asset Management Inc | 60,758 | +9,276 (+18.02%) | 0.10% | $1 M | Nov 13, 2026 |
| 68 | Quantinno Capital Management LP | 60,506 | +2,424 (+4.17%) | 0.10% | $1 M | Nov 13, 2026 |
| 69 | Rhumbline Advisers | 58,948 | -690 (-1.16%) | 0.09% | $1 M | Nov 10, 2026 |
| 70 | Fisher Asset Management, LLC | 58,546 | -7,205 (-10.96%) | 0.09% | $1 M | Nov 6, 2026 |
| 71 | Aquatic Capital Management LLC | 56,884 | New | 0.09% | $1 M | Nov 16, 2026 |
| 72 | Informed Momentum Co LLC | 55,873 | New | 0.09% | $1 M | Nov 16, 2026 |
| 73 | Price T Rowe Associates Inc /MD/ | 54,869 | 0 (0.00%) | 0.09% | $1 M | Nov 16, 2026 |
| 74 | AQR Capital Management LLC | 53,672 | +3,391 (+6.74%) | 0.09% | $1 M | Nov 16, 2026 |
| 75 | BNP Paribas Financial Markets | 53,624 | +45,428 (+554.27%) | 0.08% | $1 M | Nov 12, 2026 |
| 76 | Rafferty Asset Management, LLC | 50,998 | +6,284 (+14.05%) | 0.08% | $1 M | Nov 13, 2026 |
| 77 | Affinity Asset Advisors, LLC | 50,000 | New | 0.08% | $1 M | Nov 13, 2026 |
| 78 | SEI Investments Co | 49,913 | +33,249 (+199.53%) | 0.08% | $1 M | Nov 10, 2026 |
| 79 | Qube Research & Technologies Ltd | 49,520 | New | 0.08% | $1 M | Nov 13, 2026 |
| 80 | Panagora Asset Management Inc | 46,982 | 0 (0.00%) | 0.07% | $1 M | Nov 12, 2026 |
| 81 | D. E. Shaw & Co., Inc. | 44,654 | +300 (+0.68%) | 0.07% | $1 M | Nov 16, 2026 |
| 82 | Alliancebernstein L.P. | 44,100 | -11,640 (-20.88%) | 0.07% | $1 M | Nov 16, 2026 |
| 83 | Boothbay Fund Management, LLC | 44,049 | New | 0.07% | $1 M | Nov 16, 2026 |
| 84 | Allspring Global Investments Holdings, LLC | 38,715 | +1,515 (+4.07%) | 0.06% | $1 M | Nov 4, 2026 |
| 85 | HSBC Holdings PLC | 37,792 | New | 0.06% | $1 M | Nov 16, 2026 |
| 86 | Virtus Investment Advisers, LLC | 35,938 | -1,117 (-3.01%) | 0.06% | $1 M | Nov 12, 2026 |
| 87 | Creative Planning | 33,670 | +5,349 (+18.89%) | 0.05% | $0 M | Nov 2, 2026 |
| 88 | Susquehanna Fundamental Investments, LLC | 33,115 | +21,970 (+197.13%) | 0.05% | $0 M | Nov 16, 2026 |
| 89 | Magnetar Financial LLC | 32,021 | New | 0.05% | $0 M | Nov 13, 2026 |
| 90 | Commonwealth Equity Services, LLC | 30,677 | +2,103 (+7.36%) | 0.05% | $0 M | Nov 2, 2026 |
| 91 | Vanguard Global Advisers, LLC | 30,430 | +15,346 (+101.74%) | 0.05% | $0 M | Nov 13, 2026 |
| 92 | Campbell & CO Investment Adviser LLC | 27,207 | New | 0.04% | $0 M | Nov 13, 2026 |
| 93 | Mitsubishi UFJ Asset Management Co., Ltd. | 26,424 | -220 (-0.83%) | 0.04% | $0 M | Nov 5, 2026 |
| 94 | MetLife Investment Management, LLC | 26,057 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 95 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 25,892 | -552 (-2.09%) | 0.04% | $0 M | Nov 16, 2026 |
| 96 | Truist Financial Corp | 25,000 | 0 (0.00%) | 0.04% | $0 M | Oct 30, 2026 |
| 97 | Bridgeway Capital Management, LLC | 24,585 | -415 (-1.66%) | 0.04% | $0 M | Nov 16, 2026 |
| 98 | Empowered Funds, LLC | 24,585 | New | 0.04% | $0 M | Nov 13, 2026 |
| 99 | Kera Capital Partners, Inc. | 24,068 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 100 | Russell Investments Group, Ltd. | 23,459 | 0 (0.00%) | 0.04% | $0 M | Nov 6, 2026 |
Mutual funds holding 4D Molecular Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 1.61 M | $21 M | 2.6% | 0.20% | +22% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.59 M | $21 M | 2.5% | <0.01% | −6.9% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.18 M | $16 M | 1.9% | 0.02% | +11% | Jun 30, 2026 |
| 🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund | 788,444 | $10 M | 1.3% | 0.18% | −6.6% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc. | 681,919 | $9 M | 1.1% | 0.10% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 460,479 | $6 M | 0.74% | <0.01% | +4.3% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc. | 455,274 | $6 M | 0.73% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 412,658 | $5 M | 0.66% | 0.04% | +9.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 501,536 | $5 M | 0.80% | 0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc. | 368,160 | $5 M | 0.59% | 0.10% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 329,017 | $4 M | 0.53% | 0.05% | −2.9% | Jun 30, 2026 |
| 🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC | 388,800 | $4 M | 0.62% | 0.10% | −1.9% | Jul 31, 2026 |
| 🇺🇸 State Street SPDR S&P Kensho New Economies Composite ETFSSGA Funds Management, Inc. | 275,621 | $4 M | 0.44% | 0.13% | −11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 226,579 | $2 M | 0.36% | 0.01% | +14% | May 31, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Core FundFederated Hermes MDT Series | 209,243 | $2 M | 0.33% | 0.10% | −56% | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 158,931 | $2 M | 0.25% | 0.31% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 151,350 | $2 M | 0.24% | 0.13% | +36% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 202,979 | $2 M | 0.32% | <0.01% | −13% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 183,926 | $2 M | 0.29% | <0.01% | −12% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 171,040 | $2 M | 0.27% | 0.01% | +1.4% | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 150,812 | $1 M | 0.24% | 0.08% | +27% | May 31, 2026 |
| 🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC | 150,059 | $1 M | 0.24% | 0.36% | new | May 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 139,459 | $1 M | 0.22% | 0.03% | −1.3% | May 29, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 127,865 | $1 M | 0.20% | 0.02% | +16% | Jul 31, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 127,842 | $1 M | 0.20% | <0.01% | +21% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 126,274 | $1 M | 0.20% | 0.02% | no change | May 29, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 119,428 | $1 M | 0.19% | <0.01% | +3.9% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 86,878 | $1 M | 0.14% | 0.02% | +28% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 111,444 | $1 M | 0.18% | 0.02% | +15% | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 82,924 | $1 M | 0.13% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 99,652 | $1 M | 0.16% | 0.04% | +19% | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 86,475 | $1 M | 0.14% | 0.03% | −8.4% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 64,016 | $1 M | 0.10% | 0.04% | +17% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 76,729 | $1 M | 0.12% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 54,884 | $1 M | 0.09% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 53,185 | $1 M | 0.08% | 0.06% | −6.7% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC | 51,056 | $1 M | 0.08% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 50,241 | $1 M | 0.08% | 0.02% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 50,196 | $1 M | 0.08% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya Small Company PortfolioVoya Investments, LLC | 48,865 | $1 M | 0.08% | 0.30% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 60,927 | $1 M | 0.10% | 0.02% | +21% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 59,387 | $1 M | 0.09% | <0.01% | −4.6% | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 41,862 | $1 M | 0.07% | 0.05% | no change | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 54,661 | $1 M | 0.09% | 0.11% | −29% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 44,264 | $0 M | 0.07% | <0.01% | +389% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 33,010 | $0 M | 0.05% | 0.02% | +1.0% | Jun 30, 2026 |
| 🇺🇸 Voya MI Dynamic Small Cap FundVoya Investments, LLC | 43,888 | $0 M | 0.07% | 0.23% | new | May 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 40,842 | $0 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Invesco BuyBack AchieversTM ETFInvesco Capital Management LLC | 39,203 | $0 M | 0.06% | 0.02% | −5.5% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 28,200 | $0 M | 0.05% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 27,620 | $0 M | 0.04% | <0.01% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 35,199 | $0 M | 0.06% | 0.03% | +20% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 25,000 | $0 M | 0.04% | 0.22% | −50% | Jun 30, 2026 |
| 🇺🇸 Allspring Disciplined Small Cap FundAllspring Funds Management, LLC | 24,814 | $0 M | 0.04% | 0.18% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 31,354 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 23,671 | $0 M | 0.04% | 0.02% | +24% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 30,423 | $0 M | 0.05% | <0.01% | +3.4% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 22,589 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 19,724 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 18,530 | $0 M | 0.03% | 0.01% | +1.8% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 24,050 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 17,132 | $0 M | 0.03% | 0.02% | +17% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 21,908 | $0 M | 0.04% | 0.01% | +15% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 21,841 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 23,783 | $0 M | 0.04% | 0.12% | — | Apr 30, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 20,000 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 14,900 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 19,016 | $0 M | 0.03% | <0.01% | +231% | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 14,444 | $0 M | 0.02% | 0.02% | +8.0% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 14,339 | $0 M | 0.02% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 13,953 | $0 M | 0.02% | <0.01% | −24% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 13,903 | $0 M | 0.02% | 0.02% | +18% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 17,299 | $0 M | 0.03% | 0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 12,505 | $0 M | 0.02% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 15,939 | $0 M | 0.03% | <0.01% | +309% | Jul 31, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Core ETFFederated Advisory Services Company | 16,140 | $0 M | 0.03% | 0.06% | −59% | May 31, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 11,869 | $0 M | 0.02% | 0.07% | −5.3% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 11,491 | $0 M | 0.02% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 14,789 | $0 M | 0.02% | <0.01% | +10% | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,108 | $0 M | 0.02% | 0.06% | +28% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,952 | $0 M | 0.02% | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 13,010 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 9,707 | $0 M | 0.02% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 9,505 | $0 M | 0.02% | 0.02% | +17% | Jun 30, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Value Fund f/k/a Federated Hermes Clover Small Value FundFederated Hermes Equity Funds | 8,085 | $0 M | 0.01% | 0.06% | −92% | Jun 30, 2026 |
| 🇺🇸 Vy Jpmorgan Small Cap Core Equity PortfolioVoya Investments, LLC | 7,812 | $0 M | 0.01% | 0.03% | −5.0% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 7,801 | $0 M | 0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 7,665 | $0 M | 0.01% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 9,930 | $0 M | 0.02% | <0.01% | +4.6% | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 7,558 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 7,200 | $0 M | 0.01% | 0.02% | +19% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 7,081 | $0 M | 0.01% | 0.02% | +9.2% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 7,011 | $0 M | 0.01% | 0.02% | +37% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 6,032 | $0 M | <0.01% | 0.02% | +28% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 5,908 | $0 M | <0.01% | 0.02% | +16% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 5,842 | $0 M | <0.01% | 0.02% | −4.6% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 7,700 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 8,060 | $0 M | 0.01% | 0.04% | — | Mar 31, 2026 |
| 🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 6,808 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP | 6,762 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at 4D Molecular Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Scott BizilyChief Legal Officer | Option exercise10b5-1 plan | +1,635 | $4.140 | $7 K | 10,252 | Form 4 |
| filed | Scott BizilyChief Legal Officer | Sell10b5-1 plan | -1,635 | $12.84 | $21 K | 8,617 | Form 4 |
| filed | David KirnSee Remarks, Director | Sell10b5-1 plan | -58,061 | $12.92 | $750 K | 709,425 | Form 4 |
| filed | David KirnSee Remarks, Director | Sell10b5-1 plan | -272 | $13.61 | $4 K | 709,153 | Form 4 |
| filed | Scott BizilyChief Legal Officer | Option exercise10b5-1 plan | +1,635 | $4.140 | $7 K | 10,252 | Form 4 |
| filed | Scott BizilyChief Legal Officer | Sell10b5-1 plan | -1,635 | $13.65 | $22 K | 8,617 | Form 4 |
| filed | David KirnSee Remarks, Director | Sell10b5-1 plan | -58,333 | $13.90 | $811 K | 767,486 | Form 4 |
| filed | Scott BizilyChief Legal Officer | Option exercise10b5-1 plan | +584 | $6.490 | $4 K | 9,201 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: 4D Molecular Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 20,715 shares at $12.14
- : 6,973 shares at $12.56
- : 17,035 shares at $15.00
- : 50,000 shares at $14.68
- : 6 shares at $14.18
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
4D Molecular Therapeutics, Inc. scorecard#
Passes 4 of the 12 checks that could be worked out: strongest in financial health (4 of 5), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.42 vs -2.98Diluted EPS -2.42 in fiscal 2025 against -2.98 the year before (report's currency).
- ✗Net income higher than five years earlier-$140 M-$140 M in fiscal 2025 against -$57 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$140 MNet income -$140 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-187.2%-187.2% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-27.6%-27.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health4 of 5
- ✓Short-term assets cover short-term liabilities9.4×Current ratio 9.39 at the end of fiscal 2025.
- ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $60 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone4.49Z-score 4.49 (safe zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year7.4%Diluted shares up 7.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from 4D Molecular Therapeutics, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -187.2% | -60.5% | |
| Net margin | -164.4% | -68.9% | |
| Return on equity | -27.6% | -61.0% | |
| Debt to equity | 0.00× | 0.26× | |
| Free cash flow margin | -128.7% | -61.5% |
3of 7on the Piotroski tests of financial strength
- Net loss of $140 million, the 7th loss-making year in a row.
- Free cash flow was negative: -$110 million.
- The share count rose 7.4% in the year.
- More cash than debt: net cash of $60 million.
4D Molecular Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 85+230195%100% | 0.0−99.8%100% | 21+562%100% | 3.1−82.7%100% | 18+32.5%100% | 14+94.8%100% | 7.0—100% | |
| Research and development | 196+38.5%230% | 141+45.5%381889% | 97+21.0%469% | 80+30.8%2565% | 61+15.7%340% | 53+37.0%390% | 39—554% | |
| General and administrative | 49+5.3%57.6% | 47+27.6%125889% | 36+10.9%176% | 33+17.5%1052% | 28+62.5%155% | 17+24.1%127% | 14—199% | |
| Operating expenses | 245+30.3%287% | 188+40.6%507778% | 134+18.1%645% | 113+26.6%3617% | 89+27.2%495% | 70+21.7%516% | 58—827% | |
| Operating income | −160—−187% | −188—−507678% | −113—−545% | −110—−3517% | −71—−395% | −57—−416% | −51—−727% | |
| Interest and finance income | 19−28.0%22.9% | 27+122%73108% | 12+375%58.9% | 2.6+1778%82.2% | 0.1−9.9%0.8% | 0.2−89.9%1.1% | 1.5—21.5% | |
| Other non-operating income (expense) | 19−27.9%22.8% | 27+124%72900% | 12+374%58.1% | 2.5+15763%81.1% | 0.0—0.1% | −0.0−102%−0.2% | 1.5—20.9% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | |
| Net income including minority interests | −140—−164% | −161—−434778% | −101—−487% | −107—−3435% | −71—−395% | −57—−416% | −49—−706% | |
| Net income attributable to shareholders | −140—−164% | −161—−434778% | −101—−487% | −107—−3435% | −71—−395% | −57—−416% | −49—−706% | |
| Earnings per share, basic | -2.42—— | -2.98—— | -2.58—— | -3.32—— | -2.57—— | -8.82—— | -9.59—— | |
| Earnings per share, diluted | -2.42—— | -2.98—— | -2.58—— | -3.32—— | -2.57—— | -8.82—— | -9.59—— | |
| Shares, weighted average (basic) | 58+7.4%— | 54+37.9%— | 39+21.0%— | 32+16.7%— | 28—— | — | — | |
| Shares, weighted average (diluted) | 58+7.4%— | 54+37.9%— | 39+21.0%— | 32+16.7%— | 28+331%— | 6.4+25.0%— | 5.1—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 60−59.7%10.6% | 149−40.1%26.6% | 249+376%73.3% | 52−65.8%20.0% | 153−44.7%43.3% | 277+457%96.0% | 50—85.3% | |
| Short-term investments | 342+24.3%60.4% | 276+604%49.2% | 39−75.7%11.5% | 161+70.1%61.6% | 95—26.8% | 0—0.0% | — | |
| Receivables | — | — | — | 0−100%0.0% | 0.0−96.8%0.0% | 1.5+51.9%0.5% | 1.0—1.7% | |
| Other current assets | 10+4.2%1.8% | 10+20.3%1.8% | 8.4+20.1%2.5% | 7.0−17.7%2.7% | 8.5+90.3%2.4% | 4.4+137%1.5% | 1.9—3.2% | |
| Current assets | 413−5.0%72.9% | 435+46.6%77.6% | 297+34.5%87.3% | 221−14.0%84.2% | 256−9.3%72.5% | 283+438%98.0% | 53—90.2% | |
| Property, plant and equipment | 15−23.9%2.6% | 20−2.9%3.5% | 20−9.6%5.9% | 22+54.7%8.5% | 14+184%4.1% | 5.1+0.5%1.8% | 5.0—8.7% | |
| Right-of-use (leased) assets | 18−13.9%3.2% | 21+82.6%3.8% | 12−11.8%3.4% | 13−10.1%5.0% | 15—4.1% | 0—0.0% | — | |
| Total assets | 567+1.1%100% | 560+64.9%100% | 340+29.8%100% | 262−25.9%100% | 353+22.6%100% | 288+395%100% | 58—100% | |
| Accounts payable | 11+154%2.0% | 4.4+24.8%0.8% | 3.5+5.8%1.0% | 3.3−30.3%1.3% | 4.8+167%1.3% | 1.8+2.5%0.6% | 1.7—3.0% | |
| Current liabilities | 44+50.9%7.8% | 29+53.8%5.2% | 19+20.5%5.6% | 16−3.7%6.0% | 16−2.4%4.6% | 17+29.2%5.8% | 13—22.2% | |
| Long-term debt | 0—0.0% | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 16−16.6%2.8% | 19+64.6%3.4% | 12−14.5%3.4% | 13−11.5%5.1% | 15—4.3% | 0—0.0% | — | |
| Total liabilities | 61+22.6%10.8% | 50+55.3%8.9% | 32+5.1%9.4% | 31−11.3%11.7% | 34+7.6%9.7% | 32+13.2%11.1% | 28—48.5% | |
| Retained earnings | −716—−126% | −576—−103% | −415—−122% | −314—−120% | −207—−58.6% | −136—−47.1% | −79—−136% | |
| Shareholders' equity | 506−1.0%89.2% | 511+65.9%91.1% | 308+33.1%90.6% | 231−27.5%88.3% | 319+24.5%90.3% | 256—88.9% | −73—−125% | |
| Total liabilities and equity | 567+1.1%100% | 560+64.9%100% | 340+29.8%100% | 262−25.9%100% | 353+22.6%100% | 288+395%100% | 58—100% | |
| Shares outstanding | 58+25.8%— | 46+6.3%— | 43+32.0%— | 33+1.2%— | 32+20.8%— | 27+415%— | 5.2—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 4.7+0.9%5.5% | 4.7+10.7%12576% | 4.2+74.9%20.3% | 2.4+57.8%76.8% | 1.5+5.5%8.4% | 1.4+43.7%10.6% | 1.0—14.4% | |
| Share-based compensation | 22−15.7%25.8% | 26+32.8%70584% | 20+14.9%94.9% | 17+24.1%547% | 14+177%76.5% | 5.0+40.8%36.6% | 3.5—50.7% | |
| Cash from operating activities | −109—−128% | −135—−363743% | −76—−366% | −87—−2770% | −69—−383% | −51—−374% | −37—−525% | |
| Capital expenditure | −0.5—−0.6% | −3.8—−10232% | −2.8—−13.4% | −12—−369% | −9.1—−50.5% | −1.0—−7.3% | −3.2—−45.8% | |
| Cash from investing activities | −93—−109% | −302−361%−817397% | 116—558% | −17—−545% | −173—−957% | −1.0—−7.3% | −3.2—−45.8% | |
| Shares issued | — | — | — | 0−100%0.0% | 114−44.4%634% | 206—1511% | — | |
| Cash from financing activities | 113−66.5%133% | 337+115%911486% | 157+4984%757% | 3.1−97.4%98.6% | 118−57.7%655% | 279—2050% | −2.2—−31.4% | |
| Change in cash | −89—−105% | −100−151%−269654% | 197—949% | −101—−3217% | −124−154%−686% | 227—1668% | −42—−603% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 96+79953%100% | 4.1+4506%100% | 3.8+25107%100% | 3.0+21664%100% | 85*+8508900%100% | 0.1+2900%100% | 0.0+200%100% | 0.0−50.0%100% | 0.0*—100% | 0.0—100% | 0.0—100% | 0.0—100% | — | |
| Research and development | 261+43.9%271% | 70+41.1%1683% | 68+42.4%1806% | 65+59.7%2133% | 58*+33.7%67.7% | 49+28.5%54931% | 48+50.5%319673% | 41+46.0%290707% | 43*+65.5%4308700% | 38—1282800% | 32—637200% | 28—99536% | 26*—— | |
| General and administrative | 53+6.6%54.7% | 16+31.7%376% | 13+8.7%331% | 12−9.7%384% | 13*−2.0%15.0% | 12−6.4%13152% | 12+8.7%76800% | 13+25.7%92400% | 13*+22.9%1303100% | 13—421700% | 11—212020% | 10—36764% | 11*—— | |
| Operating expenses | 313+35.9%326% | 85+39.3%2059% | 81+35.9%2137% | 77+42.9%2516% | 70*+25.4%82.7% | 61+19.8%68083% | 59+40.1%396473% | 54+40.5%383107% | 56*+53.2%5611800% | 51—1704500% | 42—849220% | 38—136300% | 37*—— | |
| Operating income | −217—−226% | −81—−1959% | −77—−2037% | −74—−2416% | 15*—17.3% | −61—−67983% | −59—−396373% | −54—−383007% | −56*—−5611700% | −51—−1704400% | −42—−849120% | −38—−136200% | −37*—— | |
| Interest and finance income | 18−16.3%18.5% | 3.9−8.9%95.1% | 4.3−12.4%113% | 4.9−12.9%160% | 4.7*−27.3%5.5% | 4.3−40.6%4811% | 4.9−35.6%32393% | 5.6−2.8%39871% | 6.5*+47.6%646700% | 7.3—243000% | 7.5—150960% | 5.7—20518% | 4.4*—— | |
| Other non-operating income (expense) | 17−20.8%17.5% | 3.2−26.6%76.3% | 4.1−14.8%108% | 4.9−14.0%160% | 4.7*−27.4%5.5% | 4.3−40.9%4788% | 4.8−36.1%31987% | 5.6−1.5%40350% | 6.4*+47.5%644600% | 7.3—242967% | 7.5—150060% | 5.7—20482% | 4.4*—— | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—— | |
| Net income including minority interests | −200—−209% | −78*—−1883% | −73*—−1929% | −69—−2257% | 19*—22.8% | −57*—−63196% | −55*—−364387% | −48—−342657% | −50*—−4967100% | −44*—−1461433% | −35*—−699060% | −32—−115718% | −32*—— | |
| Net income attributable to shareholders | −200—−209% | −78—−1883% | −73—−1929% | −69—−2257% | 19*—22.8% | −57—−63196% | −55—−364387% | −48—−342657% | −50*—−4967100% | −44—−1461433% | −35—−699060% | −32—−115718% | −32*—— | |
| Earnings per share, basic | — | -1.08—— | -1.04—— | -1.01—— | — | -1.01—— | -0.98—— | -0.86—— | — | -0.79—— | -0.63—— | -0.66—— | — | |
| Earnings per share, diluted | — | -1.08—— | -1.04—— | -1.01—— | — | -1.01—— | -0.98—— | -0.86—— | — | -0.79—— | -0.63—— | -0.66—— | — | |
| Shares, weighted average (basic) | 72+28.7%— | 72+28.7%— | 70+25.6%— | 68+22.1%— | — | 56+1.0%— | 56+1.2%— | 56+13.1%— | — | 56—— | 55—— | 49—— | — | |
| Shares, weighted average (diluted) | 72+28.7%— | 72+28.7%— | 70+25.6%— | 68+22.1%— | — | 56+1.0%— | 56+1.2%— | 56+13.1%— | — | 56—— | 55—— | 49—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 39—9.1% | 39−19.5%9.1% | 70−8.8%14.3% | 72−45.7%14.1% | 60−59.7%10.6% | 49−74.1%11.5% | 77−59.2%16.3% | 134−51.5%25.9% | 149−40.1%26.6% | 188—31.0% | 189—30.5% | 276—43.8% | 249—73.3% | |
| Short-term investments | 268—62.5% | 268+4.4%62.5% | 291+34.7%59.1% | 318+69.4%62.1% | 342+24.3%60.4% | 257−18.4%60.5% | 216−38.8%45.6% | 188−24.9%36.4% | 276+604%49.2% | 314—52.0% | 353—56.9% | 250—39.7% | 39—11.5% | |
| Other current assets | 11—2.6% | 11+54.2%2.6% | 17+69.1%3.5% | 14+30.0%2.8% | 10+4.2%1.8% | 7.3−17.5%1.7% | 10−5.8%2.1% | 11+15.0%2.2% | 10+20.3%1.8% | 8.9—1.5% | 11—1.7% | 9.7—1.5% | 8.4—2.5% | |
| Current assets | 322—75.2% | 322+3.2%75.2% | 383+26.3%77.7% | 405+21.9%79.0% | 413−5.0%72.9% | 312−38.8%73.7% | 303−45.1%64.0% | 333−37.9%64.5% | 435+46.6%77.6% | 511—84.6% | 553—89.1% | 536—85.0% | 297—87.3% | |
| Property, plant and equipment | 11—2.6% | 11−30.5%2.6% | 12−29.3%2.5% | 14−27.5%2.6% | 15−23.9%2.6% | 16−18.7%3.8% | 18−6.7%3.7% | 19−3.7%3.6% | 20−2.9%3.5% | 20—3.3% | 19—3.0% | 19—3.1% | 20—5.9% | |
| Right-of-use (leased) assets | 16—3.7% | 16−16.7%3.7% | 17−15.8%3.4% | 17−14.8%3.4% | 18−13.9%3.2% | 19−13.1%4.5% | 20+83.8%4.1% | 20+83.2%3.9% | 21+82.6%3.8% | 22—3.6% | 11—1.7% | 11—1.8% | 12—3.4% | |
| Total assets | 429—100% | 429+1.1%100% | 493+4.0%100% | 513−0.5%100% | 567+1.1%100% | 424−29.8%100% | 474−23.6%100% | 516−18.1%100% | 560+64.9%100% | 604—100% | 620—100% | 630—100% | 340—100% | |
| Accounts payable | 7.9—1.8% | 7.9+14.8%1.8% | 13+43.9%2.5% | 15+254%2.9% | 11+154%2.0% | 6.9+135%1.6% | 8.7+154%1.8% | 4.2−1.6%0.8% | 4.4+24.8%0.8% | 2.9—0.5% | 3.4—0.6% | 4.2—0.7% | 3.5—1.0% | |
| Current liabilities | 52—12.2% | 52+41.2%12.2% | 48+37.5%9.7% | 43+61.4%8.5% | 44+50.9%7.8% | 37+25.9%8.8% | 35+78.7%7.3% | 27+64.0%5.2% | 29+53.8%5.2% | 29—4.9% | 19—3.1% | 16—2.6% | 19—5.6% | |
| Long-term debt | 20—4.6% | 20—4.6% | 20—4.0% | — | 0—0.0% | — | — | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 13—3.1% | 13−19.0%3.1% | 14−17.9%2.9% | 15−17.2%2.9% | 16−16.6%2.8% | 17−16.1%3.9% | 17+65.9%3.7% | 18+65.2%3.5% | 19+64.6%3.4% | 20—3.3% | 10—1.7% | 11—1.7% | 12—3.4% | |
| Total liabilities | 91—21.2% | 91+65.1%21.2% | 85+61.1%17.2% | 61+32.7%11.9% | 61+22.6%10.8% | 55+7.7%13.0% | 53+66.0%11.1% | 46+56.9%8.9% | 50+55.3%8.9% | 51—8.5% | 32—5.1% | 29—4.7% | 32—9.4% | |
| Retained earnings | −936—−218% | −936—−218% | −858—−174% | −785—−153% | −716—−126% | −736—−174% | −679—−143% | −624—−121% | −576—−103% | −527—−87.2% | −483—−77.8% | −448—−71.1% | −415—−122% | |
| Shareholders' equity | 338—78.8% | 338−8.4%78.8% | 408−3.1%82.8% | 452−3.8%88.1% | 506−1.0%89.2% | 369−33.3%87.0% | 421−28.5%88.9% | 470−21.8%91.1% | 511+65.9%91.1% | 553—91.5% | 588—94.9% | 601—95.3% | 308—90.6% | |
| Total liabilities and equity | 429—100% | 429+1.1%100% | 493+4.0%100% | 513−0.5%100% | 567+1.1%100% | 424−29.8%100% | 474−23.6%100% | 516−18.1%100% | 560+64.9%100% | 604—100% | 620—100% | 630—100% | 340—100% | |
| Shares outstanding | 56—— | 56+20.5%— | 55+18.2%— | 52+12.8%— | 58+25.8%— | 47−10.0%— | 47−10.0%— | 46−9.4%— | 46+6.3%— | 52—— | 52—— | 51—— | 43—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 5.0+8.9%5.2% | 1.2*−3.6%29.3% | 1.3*+9.8%33.9% | 1.3+20.7%41.6% | 1.2*+10.9%1.4% | 1.3*+6.0%1401% | 1.2*−2.3%7773% | 1.1−10.4%7507% | 1.1*−0.5%109600% | 1.2*—39667% | 1.2*—23880% | 1.2—4189% | 1.1*—— | |
| Share-based compensation | 24+0.4%25.1% | 8.3+82.7%199% | 5.9+18.7%156% | 4.5−36.3%146% | 5.6*−26.7%6.5% | 4.5−30.4%5021% | 5.0−18.4%33053% | 7.0+16.9%49900% | 7.6*+28.2%757800% | 6.5—216333% | 6.1—121460% | 6.0—21336% | 5.9*—— | |
| Cash from operating activities | −166—−173% | −57*—−1368% | −70*—−1851% | −68—−2236% | 29*—33.6% | −46*—−51664% | −43*—−289180% | −48—−341129% | −46*—−4586300% | −29*—−979700% | −30*—−604860% | −29—−103886% | −25*—— | |
| Capital expenditure | — | −0.0*—−1.2% | — | — | — | — | −0.1*—−440% | −0.6—−4507% | −0.9*—−94900% | −1.8*—−59267% | −0.3*—−6980% | −0.7—−2536% | −0.5*—— | |
| Cash from investing activities | −9.6−122%−10.0% | 25*+39.7%599% | 26*—676% | 69+116%2261% | −129*−1925%−151% | 18*−34.9%19753% | −14*—−92347% | 32—228200% | 7.1*—705900% | 27*—910033% | −74*—−1470780% | −263—−940207% | −6.7*—— | |
| Debt issued | — | 0*—0.0% | — | — | — | 0*—0.0% | — | — | — | — | — | — | — | |
| Cash from financing activities | 166+10439%173% | 0.6*+421%14.6% | 42*+4812%1120% | 11—377% | 112*+18533%132% | 0.1*−79.6%129% | 0.9*−95.0%5747% | 0−100%0.0% | 0.6*−87.4%60100% | 0.6*—18933% | 17*—344980% | 319—1138686% | 4.8*—— | |
| Change in cash | −9.5—−9.8% | −31*—−754% | −2.1*—−56.0% | 12—402% | 12*—13.7% | −29*—−31782% | −56*—−375780% | −16−160%−112929% | −38*—−3820300% | −1.5*—−50733% | −87*—−1730660% | 26—94593% | −27*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What 4D Molecular Therapeutics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Collaboration and License Revenue$85 M100%+212925%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where 4D Molecular Therapeutics, Inc. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at 4D Molecular Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025David Kirn | $2.1 M | $3.3 M | $2.7 M | $34 |
| 2024David Kirn | $1.0 M | −$6.8 M | $779 K | $25 |
| 2023David Kirn | $10.3 M | $15.4 M | $4.3 M | $91 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at 4D Molecular Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 5 · Material agreement 2 · New debt 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officersBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
3 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at 4D Molecular Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $160 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Manager, ManufacturingArchitectural and Engineering Managers | 1 | $160 K |
Where: Emeryville, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $160 K | 1 |
| FY2024 | 3 | 3 | $135 K | 3 |
| FY2023 | 1 | 1 | $130 K | 1 |
| FY2022 | 1 | 1 | $115 K | 1 |
| FY2021 | 4 | 4 | $95 K | 4 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as 4D Molecular Therapeutics, Inc.
Discuss 4D Molecular Therapeutics, Inc.#
3 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
4D Molecular Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: revenue of $4 million (up 4500% from a year earlier) and a net loss of $78 million.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of 4D Molecular Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $774,931 in 3 trades. Awards, option exercises and shares withheld for tax are not counted.
- Mutual funds: 146 funds hold $167 millionautomatic update · Jul 31, 2026
146 mutual funds in 1 country hold shares of 4D Molecular Therapeutics, Inc. worth $167 million, about 21.6% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 69 funds added shares and 43 sold; on balance they bought $25 million. Share splits are not counted as trading.
How 4D Molecular Therapeutics, Inc. compares in Biotechnology
- Market cap$637 M · higher than 61% of 726
- Revenue$85 M · higher than 68% of 647
- Net margin-208.6% · higher than 27% of 408
- Price / sales6.6× · lower than 54% of 339
- Price / book1.3× · lower than 73% of 534
- FCF yield-17.2% · higher than 47% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc.🇺🇸 | $637 M | — | -208.6% | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Catalyst Biosciences$637 M
- Autolus Therapeutics$641 M
- Arbutus Biopharma Corporation$644 M
- Sunmax Biotechnology Co., Ltd.$628 M
- Wave Life Sciences Ltd.$625 M
- AgomAb Therapeutics NV$651 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on September-2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at 4D Molecular Therapeutics, Inc.? Verify and update this profile — free
Show 4D Molecular Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.